Clinical Trial Update: A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC [Phase 2]

View source ↗

Summary

Phase 2 single-arm trial evaluating HAIC with apatinib and camrelizumab in unresectable macrotrabecular massive hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)
• HAIC (hepatic artery infusion chemotherapy)

Snippet

Sponsor: Wan-Guang Zhang | Conditions: Macrotrabecular Massive Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN